Research programme: fibrosis therapeutics - RedX Pharma

Drug Profile

Research programme: fibrosis therapeutics - RedX Pharma

Alternative Names: Porcupine inhibitor for fibrosis - RedX Pharma; ROCK2 inhibitor -RedX Pharma; Soft Pan-Rock inibitor - RedX Pharma

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Redx Pharma
  • Class Anti-inflammatories; Antifibrotics; Small molecules
  • Mechanism of Action PORCN protein inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetic nephropathies; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases; Non-alcoholic steatohepatitis

Most Recent Events

  • 30 May 2018 Redx Pharma has patent protection for Pan-ROCK inhibitors in USA
  • 01 Mar 2018 Early research in Diabetic nephropathies in United Kingdom before March 2018 (Redx Pharma pipeline, March 2018)
  • 01 Mar 2018 Early research in Inflammatory bowel disease in United Kingdom before March 2018 (Redx Pharma pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top